Clioquinol promotes the degradation of metal-dependent amyloid-ß (Aß) oligomers to restore endocytosis and ameliorate Aß toxicity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 11, 2014, Pages 4013-4018

  Matlack, Kent E S ^a   Tardiff, Daniel F ^a   Narayan, Priyanka ^a   Hamamichi, Shusei ^b,e   Caldwell, Kim A ^b   Caldwell, Guy A ^b   Lindquist, Susan ^a,c,d  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b UNIVERSITY OF ALABAMA   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Metal chelation; Phenotypic small molecule screen

Indexed keywords

8 QUINOLINOL; AMYLOID BETA PROTEIN; CLIOQUINOL; COPPER ION; IRON; OLIGOMER; ZINC ION;

ARTICLE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; ENDOCYTOSIS; ENDOSOME; IN VITRO STUDY; METAL BINDING; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION; YEAST;

METAL CHELATION; PHENOTYPIC SMALL-MOLECULE SCREEN;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CAENORHABDITIS ELEGANS; CLIOQUINOL; DRUG DISCOVERY; ENDOCYTOSIS; PROTEOLYSIS; SMALL MOLECULE LIBRARIES; YEASTS;

EID: 84896508103     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1402228111     Document Type: Article

References (42)

1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297(5580):353-356. (Pubitemid 34790756)
2. Iwatsubo T, et al. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43). Neuron 13(1):45-53.
3. Selkoe DJ, Wolfe MS (2007) Presenilin: Running with scissors in the membrane. Cell 131(2):215-221. (Pubitemid 47576152)
4. McLean CA, et al. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46(6):860-866.
5. Hartley DM, et al. (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19(20):8876-8884. (Pubitemid 30226709)
6. Khurana V, Lindquist S (2010) Modelling neurodegeneration in Saccharomyces cerevisiae: Why cook with baker's yeast? Nat Rev Neurosci 11(6):436-449.
7. Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283(44):29615-29619.
8. Treusch S, et al. (2011) Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science 334(6060):1241-1245.
9. Jarrett JT, Berger EP, Lansbury PT, Jr. (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry 32(18):4693-4697. (Pubitemid 23162022)
10. Lambert JC, et al. (2013) Meta-Analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 45(12):1452-1458.
11. Harold D, et al. (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41(10):1088-1093.
12. Seshadri S, et al. (2010) Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303(18):1832-1840.
13. Ramjaun AR, Micheva KD, Bouchelet I, McPherson PS (1997) Identification and characterization of a nerve terminal-enriched amphiphysin isoform. J Biol Chem 272(26):16700-16706. (Pubitemid 27276504)
14. Hollingworth P, et al. (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 43(5):429-435.
15. Naj AC, et al. (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 43(5):436-441.
16. Gaidos G, Soni S, Oswald DJ, Toselli PA, Kirsch KH (2007) Structure and function analysis of the CMS/CIN85 protein family identifies actin-bundling properties and heterotypic-complex formation. J Cell Sci 120(Pt 14):2366-2377. (Pubitemid 47225940)
17. Cherny RA, et al. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-Amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30(3):665-676. (Pubitemid 32607332)
18. Adlard PA, et al. (2008) Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59(1):43-55. (Pubitemid 351905863)
19. Lannfelt L, et al. (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: A phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7(9):779-786.
20. Tardiff DF, Tucci ML, Caldwell KA, Caldwell GA, Lindquist S (2012) Different 8-hydroxyquinolines protect models of TDP-43 protein, α-synuclein, and polyglutamine proteotoxicity through distinct mechanisms. J Biol Chem 287(6):4107-4120.
21. Cooper AA, et al. (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313(5785):324-328. (Pubitemid 44480951)
22. Chung CY, et al. (2013) Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science 342(6161):983-987.
23. Kim HJ, et al. (2014) Therapeutic modulation of eIF2α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet 46(2):152-160.
24. Link CD (1995) Expression of human beta-Amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA 92(20):9368-9372.
25. McColl G, et al. (2012) Utility of an improved model of amyloid-beta (Aβ1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease. Mol Neurodegener 7:57.
26. Su LJ, et al. (2010) Compounds from an unbiased chemical screen reverse both ER-To-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech 3(3-4):194-208.
27. Ferrada E, et al. (2007) Stoichiometry and conditional stability constants of Cu(II) or Zn(II) clioquinol complexes; implications for Alzheimer's and Huntington's disease therapy. Neurotoxicology 28(3):445-449. (Pubitemid 46850765)
28. Ayton S, Lei P, Bush AI (2013) Metallostasis in Alzheimer's disease. Free Radic Biol Med 62:76-89.
29. Faller P, Hureau C, Berthoumieu O (2013) Role of metal ions in the self-Assembly of the Alzheimer's amyloid-β peptide. Inorg Chem 52(21):12193-12206.
30. Smith DP, et al. (2007) Concentration dependent Cu2+ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-beta peptide. Biochemistry 46(10):2881-2891. (Pubitemid 46417926)
31. Jin L, Wu WH, Li QY, Zhao YF, Li YM (2011) Copper inducing Aβ42 rather than Aβ40 nanoscale oligomer formation is the key process for Aβ neurotoxicity. Nanoscale 3(11):4746-4751.
32. Smith DP, et al. (2006) Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge. J Biol Chem 281(22):15145-15154. (Pubitemid 43855104)
33. Raman B, et al. (2005) Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid beta peptide. J Biol Chem 280(16):16157-16162. (Pubitemid 40616741)
34. Atwood CS, et al. (1998) Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 273(21):12817-12826. (Pubitemid 28246837)
35. Kayed R, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300(5618):486-489. (Pubitemid 36444329)
36. Crouch PJ, Barnham KJ (2012) Therapeutic redistribution of metal ions to treat Alzheimer's disease. Acc Chem Res 45(9):1604-1611.
37. Bush AI, et al. (1994) Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 265(5177):1464-1467. (Pubitemid 24306803)
38. Tardiff DF, et al. (2013) Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. Science 342(6161):979-983.
39. Dudzik CG, Walter ED, Millhauser GL (2011) Coordination features and affinity of the Cu2+ site in the α-synuclein protein of Parkinson's disease. Biochemistry 50(11): 1771-1777.
40. Casals F, Bertranpetit J (2012) Genetics. Human genetic variation, shared and private. Science 337(6090):39-40.
41. Sandoe J, Eggan K (2013) Opportunities and challenges of pluripotent stem cell neurodegenerative disease models. Nat Neurosci 16(7):780-789.
42. Weiner MW, et al. (2013) The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement 9(5):e111-e194.